Research programme: tissue kallikrein serine protease inhibitors - Med Discovery/Dermadis

Drug Profile

Research programme: tissue kallikrein serine protease inhibitors - Med Discovery/Dermadis

Alternative Names: DIM-107; DM 107; hK2 inhibitors; MDKP 67b; RIK-7

Latest Information Update: 20 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Med Discovery
  • Developer Dermadis; Med Discovery; University of Zurich
  • Class
  • Mechanism of Action Peptide hydrolase inhibitors; Serine endopeptidase inhibitors; Tissue kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital ichthyosiform erythroderma
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Atopic dermatitis; Congenital ichthyosiform erythroderma; Neutropenia; Prostate cancer; Psoriasis

Most Recent Events

  • 23 Sep 2010 Preclinical trials in Congenital ichthyosiform erythroderma in France (Topical)
  • 23 Mar 2010 Preclinical trials in Atopic dermatitis in France (Topical)
  • 23 Mar 2010 Preclinical trials in Psoriasis in France (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top